Calcium dobesilate reduces endothelin-1 and high-sensitivity C-reactive protein serum levels in patients with diabetic retinopathy

Molecular Vision

Volumn 19, Issue , 2013, Pages 62-68

  Javadzadeh, Alireza ^a   Ghorbanihaghjo, Amir ^b   Adl, Farzad Hami ^a   Andalib, Dima ^a   Khojasteh Jafari, Hassan ^c   Ghabili, Kamyar ^b,d  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; DOBESILATE CALCIUM; ENDOTHELIN 1; GLUCOSE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETIC RETINOPATHY; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VISUAL ACUITY;

AGED; C-REACTIVE PROTEIN; CALCIUM DOBESILATE; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; ENDOTHELIN-1; FEMALE; HEMOSTATICS; HUMANS; LIPIDS; MALE; MIDDLE AGED; RETINAL VESSELS;

EID: 84872865238     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290:1884-90. [PMID: 14532317].
2. Støvring H, Andersen M, Beck-Nielsen H, Green A, Vach W. Rising prevalence of diabetes: evidence from a Danish pharmaco-epidemiological database. Lancet 2003; 362:537-8. [PMID: 12932388].
3. Ubink-Veltmaat LJ, Bilo HJ, Groenier KH, Houweling ST, Rischen RO, Meyboom-de Jong B. Prevalence, incidence and mortality of type 2 diabetes mellitus revisited: a prospective population-based study in The Netherlands (ZODIAC-1). Eur J Epidemiol 2003; 18:793-800. [PMID: 12974556].
4. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48-58. [PMID: 14702427].
5. Javadzadeh A. The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series. BMC Ophthalmol 2006; 6:15 .
6. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53. [PMID: 9742976].
7. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977-86. [PMID: 8366922].
8. Lam HC, Lee JK, Lu CC, Chu CH, Chuang MJ, Wang MC. Role of endothelin in diabetic retinopathy. Curr Vasc Pharmacol 2003; 1:243-50. [PMID: 15320471].
9. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia 1990; 33:306-10. [PMID: 2198188].
10. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130:963-74. [PMID: 10882379].
11. Chakrabarti S, Gan XT, Merry A, Karmazyn M, Sima AA. Augmented retinal endothelin-1, endothelin-3, endothelinA and endothelinB gene expression in chronic diabetes. Curr Eye Res 1998; 17:301-7. [PMID: 9543639].
12. Laurenti O, Vingolo EM, Desideri GB, Ferri C, Bellini C, Cassone-Faldetta M, Santucci A, De Mattia G. Increased levels of plasma endothelin-1 in non-insulin dependent diabetic patients with retinopathy but without other diabetes-related organ damage. Exp Clin Endocrinol Diabetes 1997; 105:Suppl 240-2. [PMID: 9288543].
13. Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B. Endothelin antagonism prevents diabetic retinopathy in NOD mice: a potential role of the angiogenic factor adrenomedullin. Exp Biol Med (Maywood) 2006; 231:1101-5. [PMID: 16741057].
14. Masuzawa K, Jesmin S, Maeda S, Zaedi S, Shimojo N, Miyauchi T, Goto K. Effect of endothelin dual receptor antagonist on VEGF levels in streptozotocin-induced diabetic rat retina. Exp Biol Med (Maywood) 2006; 231:1090-4. [PMID: 16741055].
15. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109:143-59. [PMID: 16033329].
16. Cilenšek I, Mankoč S, Globočnik Petrovič M, Petrovič D. The 4a/4a genotype of the VNTR polymorphism for endothelial nitric oxide synthase (eNOS) gene predicts risk for proliferative diabetic retinopathy in Slovenian patients (Caucasians) with type 2 diabetes mellitus. Mol Biol Rep 2012; 39:7061-7. [PMID: 22311033].
17. Fukumoto M, Nakaizumi A, Zhang T, Lentz SI, Shibata M, Puro DG. Vulnerability of the retinal microvasculature to oxidative stress: ion channel-dependent mechanisms. Am J Physiol Cell Physiol 2012; 302:C1413-20. [PMID: 22345512].
18. Cilenšek I, Mankoč S, Petrovič MG, Petrovič D. GSTT1 null genotype is a risk factor for diabetic retinopathy in Caucasians with type 2 diabetes, whereas GSTM1 null genotype might confer protection against retinopathy. Dis Markers 2012; 32:93-9. [PMID: 22377702].
19. Venugopal SK, Devaraj S, Jialal I. Effect of C-reactive protein on vascular cells: evidence for a proinflammatory, proatherogenic role. Curr Opin Nephrol Hypertens 2005; 14:33-7. [PMID: 15586013].
20. Kowluru RA, Abbas SN. Diabetes-induced mitochondrial dysfunction in the retina. Invest Ophthalmol Vis Sci 2003; 44:5327-34. [PMID: 14638734].
21. Bhavsar AR. Diabetic retinopathy: the latest in current management. Retina 2006; 26:S71-9. [PMID: 16832305].
22. Du Y, Miller CM, Kern TS. Hyperglycemia increases mitochondrial superoxide in retina and retinal cells. Free Radic Biol Med 2003; 35:1491-9. [PMID: 14642397].
23. Tejerina T, Ruiz E. Calcium dobesilate: pharmacology and future approaches. Gen Pharmacol 1998; 31:357-60. [PMID: 9703201].
24. Allain H, Ramelet AA, Polard E, Bentué-Ferrer D. Safety of calcium dobesilate in chronic venous disease, diabetic retinopathy and haemorrhoids. Drug Saf 2004; 27:649-60. [PMID: 15230646].
25. Szabo ME, Haines D, Garay E, Chiavaroli C, Farine JC, Hannaert P, Berta A, Garay RP. Antioxidant properties of calcium dobesilate in ischemic/reperfused diabetic rat retina. Eur J Pharmacol 2001; 428:277-86. [PMID: 11675046].
26. Rota R, Chiavaroli C, Garay RP, Hannaert P. Reduction of retinal albumin leakage by the antioxidant calcium dobesilate in streptozotocin-diabetic rats. Eur J Pharmacol 2004; 495:217-24. [PMID: 15249173].
27. Padilla E, Ganado P, Sanz M, Zeini M, Ruiz E, Triviño A, Ramírez AI, Salazar JJ, Ramírez JM, Rojas B, Hoz R, Tejerina T. Calcium dobesilate attenuates vascular injury and the progression of diabetic retinopathy in streptozotocin-induced diabetic rats. Diabetes Metab Res Rev 2005; 21:132-42. [PMID: 15386814].
28. Angulo J, Cuevas P, Fernández A, Gabancho S, Videla S, Sáenz de Tejada I. Calcium dobesilate potentiates endothelium-derived hyperpolarizing factor-mediated relaxation of human penile resistance arteries. Br J Pharmacol 2003; 139:854-62. [PMID: 12813009].
29. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18:499-502. [PMID: 4337382].
30. Zhong H, Guo L. The plasma levels of endothelin in diabetic retinopathy and their changes after treatment with doxium. Hunan Yi Ke Da Xue Xue Bao 1997; 22:56-8. [PMID: 9868029].
31. Gao MJ, Liu M, Li B, Li ML, Bian LX, Yu GN. Protective effect of calcium dobesilate against early diabetic nephropathy of rat kidney. Yao Xue Xue Bao 2009; 44:126-33. [PMID: 19408680].
32. Xia YY, Li XY, Zhang Y, Yu Y. Effects of calcium dobesilate on microinflammatory state in maintenance hemodialysis patients. Chin J Blood Purif 2006; 5:829-31.
33. Dong J, Liang CG, Zhang XQ, Li ML, Liu ZF, Zhao JJ, Yu GN. Calcium dobesilate in the treatment of early diabetic nephropathy. J Shandong Univ 2008; 46:80-3.
34. Pang IH, Yorio T. Ocular actions of endothelins. Proc Soc Exp Biol Med 1997; 215:21-34. [PMID: 9142135].
35. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag 2008; 4:1061-8. [PMID: 19183753].
36. Targher G, Bertolini L, Zoppini G, Zenari L, Falezza G. Increased plasma markers of inflammation and endothelial dysfunction and their association with microvascular complications in Type 1 diabetic patients without clinically manifest macroangiopathy. Diabet Med 2005; 22:999-1004. [PMID: 16026364].
37. Gerhardinger C, Costa MB, Coulombe MC, Toth I, Hoehn T, Grosu P. Expression of acute-phase response proteins in retinal Müller cells in diabetes. Invest Ophthalmol Vis Sci 2005; 46:349-57. [PMID: 15623795].
38. Strzalka-Mrozik B, Nowak A, Gola J, Kowalczyk M, Kapral M, Mazurek U. Factors associated with changes in endothelin-1 gene expression in patients with diabetic retinopathy in type 2 diabetes mellitus. Mol Vis 2010; 16:1272-9. [PMID: 20664700].
39. Jia ZT, Liu CY, Li H. Changes of the concentration of serum ischemia modified albumin and high sensitivity C-reactive protein in type 2 diabetic patients with retinopathy. Zhonghua Yan Ke Za Zhi 2009; 45:805-8. Chinese.[PMID: 20137285].
40. Zhu H, Shi CH. Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy using the receiver operating characteristic curve. Ophthalmic Res 2007; 39:289-93. [PMID: 17851270].
41. Barras JP, Michal M. Effect of calcium dobesilate on blood viscosity in diabetic microangiopathy. A review. Vasa 1986; 15:200-5. [PMID: 3532608].
42. Binkhorst PG, Van Bijsterveld OP. Calcium dobesilate versus placebo in the treatment of diabetic retinopathy: a double-blind cross-over study. Curr Ther Res Clin Exp 1976; 20:283-8. [PMID: 822986].
43. Freyler H. Microvascular protection with calcium dobesilate (Doxium) in diabetic retinopathy. Ophthalmologica 1974; 168:400-16. [PMID: 4598805].
44. Ribeiro ML, Seres AI, Carneiro AM, Stur M, Zourdani A, Caillon P, Cunha-Vaz JG. DX-Retinopathy Study Group. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. Graefes Arch Clin Exp Ophthalmol 2006; 244:1591-600. [PMID: 16763797].
45. Salama Benarroch I, Nano H, Pérez H, Elizalde F, Bisceglia H, Salama A. Assessment of calcium dobesilate in diabetic retinopathy. A double-blind clinical investigation. Ophthalmologica 1977; 174:47-51. [PMID: 322009].
46. Vojnikovic B. Doxium (calcium dobesilate) reduces blood hyperviscosity and lowers elevated intraocular pressure in patients with diabetic retinopathy and glaucoma. Ophthalmic Res 1991; 23:12-20. [PMID: 1870835].
47. Garay RP, Hannaert P, Chiavaroli C. Calcium dobesilate in the treatment of diabetic retinopathy. Treat Endocrinol 2005; 4:221-32. [PMID: 16053339].
48. Larsen HW, Sander E, Hoppe R. The value of calcium dobesilate in the treatment of diabetic retinopathy. A controlled clinical trial. Diabetologia 1977; 13:105-9. [PMID: 323093].
49. Rasch R. Capillary fragility and doxium. A controlled clinical trial. Diabetologia 1973; 9:483-5. [PMID: 4773549].
50. Haritoglou C, Gerss J, Sauerland C, Kampik A, Ulbig MW. CALDIRET study group. Effect of calcium dobesilate on occurrence of diabetic macular oedema (CALDIRET study): randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2009; 373:1364-71. [PMID: 19376452].
51. Schram MT, Stam F, de Jongh RT, de Vries G, van Dijk RA, Serné EH, Lampe D, Nanayakkara PW, Tushuizen ME, Scheffer PG, Schalkwijk CG, Kamper AM, Stehouwer CD. The effect of calcium dobesilate on vascular endothelial function, blood pressure, and markers of oxidation in obese male smokers: a placebo-controlled randomised clinical trial. Atherosclerosis 2003; 170:59-72. [PMID: 12957683].
52. Benarroch IS, Brodsky M, Rubinstein A, Viggiano C, Salama EA. Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res 1985; 17:131-8. [PMID: 4011126].
53. Beyer J, Meissner KO, Happ J, Cordes U. Effect of calcium dobesilate on permeation of plasma proteins in diabetic patients. Dtsch Med Wochenschr 1980; 105:1604-8. [PMID: 6160031].